Organon & Co. (NYSE:OGN) Posts Earnings Results

Organon & Co. (NYSE:OGN - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09), Zacks reports. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Price Performance

OGN stock traded down $1.03 during midday trading on Monday, hitting $15.30. The company's stock had a trading volume of 4,424,393 shares, compared to its average volume of 2,305,809. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company has a 50 day moving average of $15.35 and a two-hundred day moving average of $17.38. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of 3.03, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.32%. The ex-dividend date is Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 22.22%.

Analysts Set New Price Targets

OGN has been the topic of several analyst reports. Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday. Finally, TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Organon & Co. currently has a consensus rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.